Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5699971 | 0.81 | CA12 (0.49) | PTGS1PTGS2SMN1; SMN2TDP1SLC6A2 | |
| SCHEMBL18229376 | 0.80 | L3MBTL1 (0.47) | GAAATRCYP17A1 | |
| SCHEMBL15596168 | 0.79 | CHRNB2 (0.47) | TDP1CHRNB4CHRNA3CYP17A1NOTUM | |
| SCHEMBL15858729 | 0.79 | CHRNB4 (0.50) | PTGS1PTGS2GAASMN1; SMN2SLC6A2 | |
| SCHEMBL10549246 | 0.78 | — | — | |
| SCHEMBL29682155 | 0.78 | — | — | |
| SCHEMBL6640028 | 0.78 | CA12 (0.39) | PTGS1PTGS2SMN1; SMN2SLC6A2SLC6A4 | |
| SCHEMBL764171 | 0.78 | CHRNB4 (0.33) | CHRNB4CHRNA3CA12CA1CA2 | |
| SCHEMBL14159678 | 0.76 | CA12 (0.49) | GAASMN1; SMN2SLC6A2SLC6A4CHRNB4 | |
| SCHEMBL31139331 | 0.75 | CYP11B1 (0.41) | CHRNB4CHRNA3CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-9724351-B2 | Compounds for the treatment of paramoxyvirus viral infections | ALIOS BIOPHARMA, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9724351-B2 | Compounds for the treatment of paramoxyvirus viral infections | ALIOS BIOPHARMA, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | disclosed |
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | disclosed |
| WO-2014031784-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | ALIOS BIOPHARMA, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| CN-100516066-C | Compounds for treating impaired fundic relaxation | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-22 | — | — | CN | disclosed |
| US-7423048-B2 | Compounds for treating fundic disaccomodation | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-09-09 | — | — | US | disclosed |
| EP-1636239-B1 | INDOLE DERIVATIVES WITH AN IMPROVED ANTIPSYCHOTIC ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-18 | — | — | EP | disclosed |
| US-20060142318-A1 | Compounds for treating fundic disaccomodation | VAN EMELEN KRISTOF | 2006-06-29 | — | — | US | disclosed |
| CN-1781921-A | Compounds for treating impaired fundic relaxation | JANSSEN PHARMACEUTICA NV (BE) | 2006-06-07 | — | — | CN | disclosed |
| EP-1636239-A1 | INDOLE DERIVATIVES WITH AN IMPROVED ANTIPSYCHOTIC ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-22 | — | — | EP | disclosed |
| EP-1296987-B1 | COMPOUNDS FOR TREATING IMPAIRED FUNDIC RELAXATION | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004106346-A1 | INDOLE DERIVATIVES WITH AN IMPROVED ANTIPSYCHOTIC ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004106298-A1 | INDOLE DERIVATIVES WITH AN IMPROVED ANTIPSYCHOTIC ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-09 | — | — | WO | disclosed |
| US-20040019051-A1 | Compounds for treating impaired fundic relaxation | JANSSEN-CILAG S.A. (ES) | 2004-01-29 | — | — | US | disclosed |
| CN-1437602-A | Compounds for treating impaired fundic relaxation | JANSSEN PHARMACEUTICA NV (BE) | 2003-08-20 | — | — | CN | disclosed |
| EP-1296987-A1 | COMPOUNDS FOR TREATING IMPAIRED FUNDIC RELAXATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001098306-A1 | COMPOUNDS FOR TREATING IMPAIRED FUNDIC RELAXATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | SARS1, MAVS, ZC3HAV1 | PTGS1 1058/4885PTGS2 1434/4885GAA 863/4885 |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | PTGS1 1527/4885PTGS2 1848/4885GAA 733/4885 |
| US-20040019051-A1 | Compounds for treating impaired fundic relaxation | CNR2, CNR1, CBR1 | PTGS1 119/4885PTGS2 391/4885GAA 2754/4885 |
| US-20060142318-A1 | Compounds for treating fundic disaccomodation | ALK, ADORA1, CHRM2 | PTGS1 1679/4885PTGS2 1813/4885GAA 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.